{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"The outcome reported here is the number (%) of participants who experienced grade 3 or greater toxicity while on study.\n\nA summary of the individual toxicities can be found in the AE/SAE results.","groups":[{"description":"Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.\n\nromidepsin: DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.","id":"OG000","title":"Treatment (Single-agent Depsipeptide)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"During treatment (max of 16 months) and for 1 month following treatment","title":"Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3","type":"PRIMARY","unitOfMeasure":"Participants"}